2011
C-met as a therapeutic target using ARQ 197 in renal cell carcinoma.
Gibney G, Conrad P, Aziz S, Camp R, Schwartz B, Chen C, Kelly W, Kluger H. C-met as a therapeutic target using ARQ 197 in renal cell carcinoma. Journal Of Clinical Oncology 2011, 29: 360-360. DOI: 10.1200/jco.2011.29.7_suppl.360.Peer-Reviewed Original ResearchRCC cell linesAutomated Quantitative AnalysisRenal cell carcinomaC-Met expressionCell linesC-MetNormal cellular growthARQ 197Receptor tyrosine kinasesVon Hippel-Lindau (VHL) geneCell carcinomaC-Met activationAdjacent normal renal tissuesC-Met mutationsInhibits cell growthTherapeutic targetIndependent predictorsDown-stream mediatorsCellular arrestTyrosine kinaseCellular growthC-Met proteinVascular developmentRCC cellsClear cell histologic subtype
2009
Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib
Jilaveanu L, Zito C, Lee SJ, Nathanson KL, Camp RL, Rimm DL, Flaherty KT, Kluger HM. Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib. Clinical Cancer Research 2009, 15: 1076-1085. PMID: 19188183, PMCID: PMC4263281, DOI: 10.1158/1078-0432.ccr-08-2280.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBenzenesulfonatesCarboplatinCell Line, TumorDisease-Free SurvivalDrug Delivery SystemsHumansMelanomaMitogen-Activated Protein Kinase 3NiacinamidePaclitaxelPhenylurea CompoundsPyridinesReceptors, Vascular Endothelial Growth FactorSkin NeoplasmsSorafenibTreatment OutcomeConceptsSerine/threonine-protein kinase 1Mitogen-activated protein kinase pathwayHigher ERK1/2Protein kinase 1Fibroblast growth factor receptor 1Protein kinase pathwayReceptor tyrosine kinasesPlatelet-derived growth factor receptor betaGrowth factor receptor betaVEGF-R2 expressionSorafenib targetsB-RAF V600E mutationGrowth factor receptor 1C-RafKinase pathwayVascular endothelial growth factor receptor 2B-RafKinase 1Kinase 1/2Tyrosine kinaseEndothelial growth factor receptor 2Factor receptor 1ERK1/2Kinase inhibitorsMultitarget kinase inhibitor